A federal court ruling that invalidated a patent protecting Eli Lilly and Co.'s cancer drug Gemzar surprised at least one analyst covering the company but stirred little reaction from investors in trading Tuesday.
Patent ruling on Lilly drug stirs some surpriseCourtesy Newsvine - business Tue, 08/18/2009 - 13:44
A federal court ruling that invalidated a patent protecting Eli Lilly and Co.'s cancer drug Gemzar surprised at least one analyst covering the company but stirred little reaction from investors in trading Tuesday. Related itemsDrugmaker Eli Lilly reports 4Q profit, sales jump
Bristol-Myers: Liver cancer drug failed in study
Court issues restraining order against Eli Lilly
BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
Uniden TRU9496 2-Line Corded/Cordless Digital...
|
Popular by tags Week |
Post new comment